A Trial of Two Daclizumab Dosing Strategies vs. No Induction Treatment With Tacrolimus, Mycophenolate Mofetil , & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients

Exclusion Criteria

• •Prior treatment with daclizumab
• •Known sensitivity or contraindication to tacrolimus, MMF, or steroids
• •Patient with significant or active infection
• •Patients with a positive lymphocytotoxic crossmatch using donor lymphocytes and recipient serum
• •Patients whose life expectancy is severely limited by diseases other than renal disease
• •Ongoing substance abuse, drug or alcohol
• •Major ongoing psychiatric illness or recent history of noncompliance
• •Insufficient cardiovascular reserve
• •Malignancy within last 5 years, excluding nonmelanoma skin cancers
• •Serologic evidence of infection with HIV or Hepatitis B surface antigen positive
• •Investigational drug within 30 days prior to transplant surgery
• •Anti-T cell therapy within 30 days prior to transplant surgery